Sponsor Pipeline

National Cancer Centre, Singapore Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
36
Active Trials
23
Recruiting
1
Phase 3
10
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-04 NCT07745816 Effectiveness and Implementation of 'Supportive and Palliative Care Review Kit in… Not Yet Recruiting
2026-07-29 NCT07733973 Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator… Not Yet Recruiting
Active Trials by Phase
Phase 3
1
Phase 2
12
Phase 1
1
Not specified
22
Active Trials — top 25 of 36
NCT IDTitleConditionStatus
Phase 3
NCT07583979 Electroacupuncture for Cognitive Toxicity in Cancer Survivors: Assessing Implementation… Cancer-related Cognitive Impairment Not Yet Recruiting
Phase 2
NCT06160843 Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma Relapsed Peripheral T-Cell Lymphoma Recruiting
NCT05377034 Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin… Locally Advanced Hepatocellular Carcinoma Recruiting
NCT06093061 Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk… Nasopharyngeal Carcinoma Recruiting
NCT05929885 Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in… Metastatic Pancreatic Cancer Recruiting
NCT05516628 Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant… Hepatocellular Carcinoma Recruiting
NCT04912765 Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC Hepatocellular Carcinoma Recruiting
NCT04946968 Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low… Advanced Solid Tumours Active, Not Recruiting
NCT04027647 Phase 2 Study of Dacomitinib in NSCLC NSCLC Stage IIIB Active, Not Recruiting
NCT03097939 Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma Active, Not Recruiting
NCT05773092 A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC NSCLC Active, Not Recruiting
NCT05286437 Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Active, Not Recruiting
NCT07521670 Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary… Recurrent Adenoid Cystic Carcinoma Not Yet Recruiting
Phase 1
NCT06587295 Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With… Advanced Solid Tumor Recruiting
Not specified
NCT05517135 tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an… Nasopharyngeal Carcinoma Recruiting
NCT04340024 Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients Nasopharyngeal Cancer Recruiting
NCT06418412 A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer Recruiting
NCT04986748 Using QPOP to Predict Treatment for Sarcomas and Melanomas Sarcoma Recruiting
NCT05957068 Breast Cancer Exercise Intervention Study Early-stage Breast Cancer Recruiting
NCT06977360 Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the… Breast Cancer Recruiting
NCT07428356 Histotripsy for Ablation of Liver Tumours in Asia Liver Malignant Tumors Recruiting
NCT04738708 Telegenetics or In-Person Genetic Counselling Genetic Counselling Recruiting
NCT06044441 Evaluation and Implementation Preparation of a Proactive Palliative Care Model (ENABLE-SG) Neoplasms Recruiting
NCT02806388 Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project Solid Tumor Recruiting
NCT06956248 Innovating Access to Novel Therapies Through Standardized Prospective Integration of… Solid Tumor Recruiting
See all 36 active National Cancer Centre, Singapore trials with filters →
Disease Areas
Get alerts when National Cancer Centre, Singapore's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free